VaxInnate Corporation
3 Cedar Brook Drive
Suite 1
Cranbury
New Jersey
08512
United States
Tel: 609 860 2260
Fax: 609 860 2290
Website: http://www.vaxinnate.com/
45 articles about VaxInnate Corporation
-
VaxInnate Corporation Awarded Contract by the U.S. Government To Develop Recombinant Seasonal and Pandemic Flu Vaccines
3/1/2011
-
VaxInnate Corporation's Novel Recombinant Flu Vaccine Named a Top 10 Biopharma Project to Watch in 2011
11/1/2010
-
Dr. Thomas Hofstaetter Named President and CEO of VaxInnate Corporation
3/18/2010
-
VaxInnate Corporation Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine to Biological E. Limited; Vaccine Could Become Available for Use in India This Year
1/12/2010
-
Former Wyeth Executive Joins VaxInnate Corporation as Chief Operating Officer
12/9/2009
-
3M Drug Delivery Systems Licenses Vaccine Adjuvants to VaxInnate Corporation
11/9/2009
-
VaxInnate Corporation Reports Positive Results from Preclinical Testing of Swine Flu Vaccine Developed Using Novel Technology
6/17/2009
-
VaxInnate Corporation Closes $30 Million Round of Financing; Wellcome Trust Leads Round
5/6/2009
-
VaxInnate Corporation's Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study
4/27/2009
-
VaxInnate Corporation Raising $30 Million
3/26/2009
-
VaxInnate Corporation Welcomes David J. Williams to its Board of Directors
2/19/2009
-
VaxInnate Corporations Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study
10/27/2008
-
VaxInnate Corporation to Present Positive Results from Clinical Trial of Universal Flu Vaccine Candidate at ICAAC/Infectious Diseases Society of AmericaMeeting
10/14/2008
-
VaxInnate Corporation's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009
9/30/2008
-
VaxInnate Corporation's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
8/21/2008
-
VaxInnate Corporation to Discuss Seasonal and Pandemic Flu Vaccines During Biotechnology Industry Organization (BIO) 2008 This Week
6/16/2008
-
VaxInnate Corporation Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
9/25/2007
-
VaxInnate Corporation Awarded National Institutes of Health (NIH) Funding for Collaborative Dengue Fever Vaccine Development
7/23/2007
-
Two Significant Hires Round-Out VaxInnate Corporation's Core Management Team
6/6/2007
-
U.S. Congressman Rush Holt Visits VaxInnate Corporation To Announce Government Funding For Collaborative Malaria Vaccine Development
11/30/2006